Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation with human recombinant autoantigens.

Ake Lernmark1, Carl-David Agardh

  • 1The University of Washington, Department of Medicine, Seattle, WA 981905, USA. ake@u.washington.edu

Trends in Immunology
|September 13, 2005
PubMed
Summary

Type 1 diabetes involves a T cell attack on beta cells. Immunomodulation with autoantigens like oral insulin or GAD65 shows promise in altering disease course and protecting beta cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk estimation and dynamic prediction using discrete-time joint models for longitudinal and multistate data with interval and state censoring.

Biostatistics (Oxford, England)·2026
Same author

Retinol, Carotenoid, and Tocopherol Intake and Status, and the Risk of Islet Autoimmunity and Type 1 Diabetes: The Environmental Determinants of Diabetes in the Young Study.

Diabetes/metabolism research and reviews·2026
Same author

Heterogeneity between insulin and proinsulin in the potency for insulin autoantibodies in newly diagnosed type 1 diabetes children.

Clinical and experimental immunology·2026
Same author

Polymorphisms in intron 1 of HLA-DRA differentially associate with type 1 diabetes and celiac disease and implicate involvement of complement system genes C4A and C4B.

eLife·2026
Same author

Thyroid autoimmunity and the subsequent development of islet and celiac autoimmunity in the TEDDY study.

American journal of epidemiology·2026
Same author

Profiling Associations Between IGHG-FCGR Ligand-Receptor Interactions and Disease Progression From Stage 1 and 2 to Stage 3 Type 1 Diabetes.

Diabetes·2025

Area of Science:

  • Immunology
  • Endocrinology
  • Autoimmune Diseases

Background:

  • Type 1 diabetes results from autoimmune destruction of pancreatic beta cells.
  • Autoantibodies to GAD65, IA-2, and insulin are key biomarkers predicting disease onset.
  • Preclinical models suggest autoantigen-based immunomodulation can impact autoimmune diabetes progression.

Purpose of the Study:

  • To explore the potential of autoantigen-based immunomodulation in type 1 diabetes.
  • To evaluate the safety and immunomodulatory effects of GAD65 in latent autoimmune diabetes in adults (LADA).
  • To identify strategies for future immunomodulation trials, including subject stratification and combination therapies.

Main Methods:

  • Review of preclinical studies in diabetic rodents.
  • Analysis of clinical data on oral insulin administration in at-risk individuals.
  • Assessment of safety and immunomodulatory effects of alum-formulated GAD65 in LADA patients.

Main Results:

  • Oral insulin reduced diabetes development in high-risk subjects with insulin autoantibodies.
  • Alum-formulated GAD65 administration was safe in LADA patients and suggested immunomodulatory activity.
  • Autoantibodies are predictive of type 1 diabetes development.

Conclusions:

  • Autoantigen-based therapies, such as oral insulin and GAD65, show potential for altering the course of autoimmune diabetes.
  • Future trials could refine subject selection using HLA genetics and residual insulin production.
  • Combining autoantigens with agents like anti-CD3 antibodies may induce antigen-specific tolerance for long-term beta cell protection.

Related Experiment Videos